Empros Pharma
CompanySweden
Empros Pharma AB develops one asset, in phase 2 (EMP16-02 in obesity & overweight). Mostly small molecule acting on lipid and ceramide metabolism, glycolysis and LIPC; based in Sweden.
- Assets
- 1
- Furthest
- Phase 2
- Trials
- 3
- Signals
- 0
Pipeline
1Inhibits alpha-glucosidase and pancreatic lipase to reduce carbohydrate and fat absorption.
Phase 2Small moleculeLipid and ceramide metabolismGlycolysisobesity & overweightoverweight or obese
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms4
- Trials3
- Similar companies6
Updated 7 Oct 2026 · 9 sources